RPG Life Sciences Q1FY27 revenue up 15.8% to ₹195.7 cr

Key earnings snapshot for Q1FY27

RPG Life Sciences Limited reported a steady improvement across revenue and operating profitability for the quarter ended June 30, 2026 (Q1FY27). Revenue from operations rose 15.8% year-on-year to ₹195.7 crore, compared with ₹168.9 crore in Q1FY26. EBITDA increased 17.9% to ₹48.0 crore from ₹40.7 crore a year earlier. The EBITDA margin expanded by 40 basis points to 24.5% from 24.1%, indicating tighter cost control and improved operating discipline as stated in the disclosure. The company also reported growth in net profit on both standalone and consolidated bases. The reported numbers were approved by the Board of Directors on July 28, 2026.

Board approval and audit review process

The unaudited standalone and consolidated financial results for Q1FY27 were approved at the Board meeting held on July 28, 2026. The company said the results were reviewed by the Audit Committee before being placed before the Board. The financials were subjected to a limited review by the statutory auditors, S R B C & Co LLP. The company referenced Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the process followed. Rajesh Shirambekar, Head-Legal and Company Secretary, signed the press release dated July 28, 2026. These steps are part of standard disclosure and compliance requirements for listed companies.

Revenue growth and total income movement

Revenue from operations came in at ₹195.7 crore for Q1FY27, rising from ₹168.9 crore in the corresponding quarter last year. Total income increased to ₹199.85 crore from ₹174.15 crore in Q1FY26. While operating revenue rose sharply, other income declined during the quarter. Other income was reported at ₹0.416 crore compared with ₹0.523 crore in Q1FY26, with the company attributing the drop to lower non-operating receipts. The widening gap between operating performance and non-operating income highlights that the quarter’s improvement was primarily driven by core operations. The company did not flag any exceptional items in Q1FY27.

Operating performance and margin expansion

EBITDA increased to ₹48.0 crore in Q1FY27 from ₹40.7 crore in Q1FY26, translating into a 17.9% year-on-year rise. The EBITDA margin improved to 24.5% from 24.1%, an expansion of 40 basis points. The company linked margin improvement to better operating discipline, as per the release. With revenue growth outpacing the increase in certain costs, the company was able to convert a larger share of sales into operating profit. This margin movement is a key indicator watched by investors because it often reflects cost control and efficiency. The numbers disclosed point to improved profitability even as the company referenced broader market volatility.

Profitability: standalone vs consolidated

Standalone net profit rose 16.3% to ₹3.057 crore in Q1FY27 from ₹2.63 crore in Q1FY26, based on the figures provided. Consolidated net profit increased 17% to ₹3.076 crore. The company also reported earnings per share (basic and diluted) of ₹18.49 compared with ₹15.90 in the corresponding quarter of the previous year. Consolidated EPS was reported at ₹18.60 versus ₹15.90 previously. The disclosure noted that there were no exceptional items in Q1FY27, unlike the previous fiscal year when results were impacted by insurance claims and new labour codes. The absence of exceptional items can improve comparability across periods.

Reported numbers vs Uniresearch estimate

Alongside the company’s reported Q1FY27 numbers, the provided text also includes an external forecast item labeled as a Uniresearch estimate (updated June 29, 2026). That estimate projected Q1 FY27 revenue of ₹173 crore (+2.4% YoY) and PAT of ₹25 crore (-3.7% YoY), using Q1 FY26 actuals of ₹169 crore revenue and ₹26 crore PAT as the base. These forecast figures differ substantially from the company’s reported Q1FY27 revenue from operations of ₹195.7 crore and standalone PAT of ₹3.057 crore. Because the forecast is clearly marked as a prediction, it should be interpreted as an estimate rather than a company filing. Investors typically distinguish between company-reported results and third-party projections when assessing performance.

Corporate governance update: independent director cessation

RPG Life Sciences also announced the cessation of Ms. Zahabiya Khorakiwala as an Independent Director, effective July 26, 2026. The text further notes a revised composition with Ms. Radhika Gupta in the leadership role, and Mr. Sachin Nandgaonkar and Mr. Ashok Nair serving as members. While the specific committee is not named in the provided content, such updates are typically relevant for governance oversight and statutory compliance. The timing of the change is close to the Q1FY27 board approval date, making it a notable corporate update for stakeholders tracking board and committee composition.

Table: Q1FY27 financial performance highlights

Market impact: what the numbers signal

The quarter’s disclosures point to a combination of higher operating revenue and improved operating margin. The rise in EBITDA and the 40 bps margin expansion indicate better operating leverage during the period. Other income declined year-on-year, suggesting the earnings improvement was not supported by higher non-operating gains. The company highlighted its ability to drive profitability despite broader market volatility, and the reported increase in EPS supports that view for the quarter. The note on “no exceptional items” also matters because it suggests the period’s profitability was not boosted or reduced by one-off adjustments.

Conclusion

RPG Life Sciences’ Q1FY27 results showed higher revenue, stronger EBITDA, and improved margin, with standalone and consolidated net profit both rising year-on-year. The Board approved the unaudited results on July 28, 2026 after Audit Committee review and a limited review by S R B C & Co LLP. The company also disclosed a board-level change with the cessation of an independent director effective July 26, 2026. Investors will typically track subsequent filings and updates for additional detail on business drivers and governance changes beyond the headline financial metrics.